Daiichi scores in PhIII study of AML drug, beating chemo and building its case for worldwide approvals
An AML drug picked up by Daiichi Sankyo in its Ambit buyout has outshone chemotherapy in a late-stage trial, setting up the Japanese drugmaker to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
